Sherrie B. Holdman, Ph.D.

Sherrie works with clients across a broad range of technologies, including gene editing and CRISPR systems; antibody and peptide therapeutics; oligonucleotides; diagnostics; cell and gene therapies; pharmaceutical formulations; and artificial intelligence (AI) enabled platforms. Her practice further includes preparing and advising on legal opinions, freedom to operate (FTO) assessment, and invalidity analyses to support strategic decision making and mitigate litigation risk. Sherrie also counsels clients on life-cycle management strategies that align patent protection with Food and Drug Administration (FDA) regulatory considerations to support long-term product development and portfolio value. She regularly supports IP due diligence in connection with financings, mergers, and acquisitions. She also holds a Chinese patent agent qualification. 

Sherrie previously served as patent counsel at a global biopharmaceutical company, where she directed strategy and prosecution for international patent portfolios and supported IP related transaction negotiations.